Marksans Pharma’s arm gets Marketing Authorization for Levonorgestrel Tablets from UK MHRA

02 Aug 2024 Evaluate

Marksans Pharma’s wholly owned subsidiary -- Relonchem has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill. It is to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurred. 

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.


Marksans Pharma Share Price

291.60 2.10 (0.73%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.